COVID-19: WHAT HAVE WE LEARNED SINCE THE BEGINNING OF THE EPIDEMIC UNTIL TODAY?
Keywords:
coronavirus, COVID-19, pandemic, pneumonia
Abstract
At the end of December 2019, in the city of Wuhan in China, the appearance of unknown viral pneumonia was recorded in a large number of patients. The cause of this infection was soon discovered - a new coronavirus, called SARS-CoV-2 due to its genetic similarity to the virus that causes severe acute respiratory syndrome (SARS-CoV). The infection has spread rapidly to other continents, and the pandemic is still ongoing. The clinical presentation varies from asymptomatic form, through symptoms of upper respiratory tract infection, to pneumonia and acute respiratory distress syndrome (ARDS). At the risk for severe disease are elderly, immunocompromised and chronic internist patients. The virus enters cells via angiotensin converting enzyme 2 (ACE2) receptor which is present in all tissues in the body. In addition to interstitial pneumonia, pathological changes are also found in other organ systems. The first case in Serbia was recorded on March 6, 2020. A large number of patients required the engagement of health workers of all profiles and the introduction of a large number of health institutions in the COVID system. The emergence of a new virus necessitated a new antiviral drug. Based on previous experience with the SARS-CoV virus, antiviral drugs known from before have been used, with varying degrees of success. The therapy changed in accordance with new knowledge, and since the beginning of the epidemic in Serbia, a National protocol for the treatment of COVID-19 has been established, which has kept pace with the recommendations of the world's leading institutions. The most significant event during the pandemic is the appearance of the vaccine against COVID-19 and vaccination in Serbia began in December 2020. The speed of pandemic completion depends directly on the speed and efficiency of vaccination, along with other epidemiological measures.
References
1. Chams, N.; Chams, S.; Badran, R.; Shams, A.; Araji, A.; Raad, M.; Mukhopadhyay, S.; Stroberg, E.; Duval, E.; Barton, L.; Hussein, I. COVID-19: A Multidisciplinary Review . Front Public Health. 2020, 8, 383; doi: 10.3389/fpubh.2020.00383.
2. WHO. Clinical management of COVID-19: living guidance.Jan 25, 2021. Geneva: World Health Organization, 2021.
3. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science.2020, 367, 1444-1448. doi: 10.1126/science.abb2762.
4. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J. i saradnici. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020, 382,727-733. doi: 10.1056/NEJMoa2001017.
5. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006, 66,193–292. Doi: 10.1016/S0065-3527(06)66005-3.
6. Cevik, M.; Kuppalli, K.; Kindrachuk, J.; Peiris, M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020, 371. doi: 10.1136/bmj.m3862.
7. Shereen,MA.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020, 24, 91–8. doi: 10.1016/j.jare.2020.03.005.
8. Cheng, A.; Zhang, W.; Xie, Y.; Jiang, W.; Arnold, E.; Sarafianos, SG. i saradnici. Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology. 2005, 335, 165–176. doi: 10.1016/j.virol.2005.02.017.
9. Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020, 10, 102–108. doi: 10.1016/j.jpha.2020.03.001.
10. Li, G.; Fan, Y.; Lai, Y.; Han, T.; Li, Z.; Zhou, P. i saradnici. Coronavirus infections and immune responses. J Med Virol. 2020, 92, 424–432. doi: 10.1002/jmv.25685.
11. Zhou, Y.; Fu, B.; Zheng, X.; Wang, D.; Zhao, C.; Qi, Y.; Sun, R.; Tian, Z.; Xu, X.; Wei, H. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. National Science Review. 2020, 7, 998–1002.https://doi.org/10.1093/nsr/nwaa041.
12. Mahallawi, W.H.; Khabour, O.F.:, Zhang, Q.; Makhdoum, H.M.: Suliman, B.A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018,104, 8–13. doi: 10.1016/j.cyto.2018.01.025.
13. Wong, C.K.; Lam, C.W.K.; Wu, A.K.L. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2014, 136, 95–103.doi: 10.1111/j.1365-2249.2004.02415.x.
14. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46, 846–848. doi: 10.1007/s00134-020-05991-x.
15. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y. i saradnici . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.2020, 395,497–506. doi: 10.1016/S0140-6736(20)30183-5.
16. Dienz, O.; Rincon, M. The effects of IL-6 on CD4 T cell responses. Clin. Immunol.2009, 130, 27–33. doi:10.1016/j.clim.2008.08.018.
17. Yang, R.; Masters, A.R.; Fortner, K.A.; Champagne, D.P.; Yanguas-Casas, N.; Silberger, D.J.; Weaver, C.T.; Haynes, L.; Rincon, M. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. J. Exp. Med. 2016, 213, 2281–2291. doi:10.1084/jem.20160417.
18. Hussman, J.P. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention.Front Pharmacol.2020, 11, 1169. doi: 10.3389/fphar.2020.01169.
19. Varga, Z. Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R. i saradnici. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395, 1417-1418. doi:https://doi.org/10.1016/S0140-6736(20)30937-5.
20. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X. i saradnici. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382, 1708–1720. doi: 10.1056/NEJMoa2002032.
21. Bhatraju, P.K.; Ghassemieh, B.J.; Nichols, M.; Kim, R.; Jerome, K.R.; Nalla, A.K. i saradnici. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020, 382,2012–2022. doi: 10.1056/NEJMoa2004500.
22. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; Mcginn, T.; Davidson, K.W. i saradnici. Presenting characteristics, comorbidities, outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323, 2052–2059. doi:10.1001/jama.2020.6775.
23. Giacomelli, A.; Pezzati, L.; Conti, F.; Bernacchia, D.; Siano, M.; Oreni, L. i saradnici. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020, 71, 889-890.doi: 10.1093/cid/ciaa330.
24. Wang, Y.; Liu, Y.; Liu, L.; Wang, X.; Luo, N.; Ling, L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. 2020, 221, 1770–1774. doi: 10.1093/infdis/jiaa119.
25. Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020, 25,2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
26. Pelemiš M.; Stevanović, G.; Turkulov, V.; Vučinić, V.; Matijašević, J.; Milošević, B.; Milošević, I. i saradnici. Nacionalni protokol Republike Srbije za lečenje COVID-19 infekcije,Verzija 11. 2021.
27. Wu, Z.; Mcgoogan, J.M. Characteristics of important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control Prevention. JAMA. 2020, 323, 1239–1242. doi: 10.1001/jama.2020.2648.
28. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z. i saradnici. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395, 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
29. Goyal, P.; Choi, J.J.; Pinheiro, L.C.; Schenck, E.J.; Chen, R.; Jabri, A. i saradnici . Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020, 382, 2372–2374. doi: 10.1056/NEJMc2010419.
30. Chow, N.; Fleming-Dutra, K.; Gierke, R.; Hall, A.; Hughes, M.; Pilishyili, T. i saradnici. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69, 382–386. doi: 10.15585/mmwr.mm6913e2.
31. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; Mcginn, T.; Davidson K.W. i saradnici. . Presenting characteristics, comorbidities, outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323, 2052–2059. doi: 10.1001/jama.2020.6775.
32. Simonnet. A.; Chetboun, M.; Poissy, J.; Raverdy, V.; Noulette, J.; Duhamel, A. i saradnici. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020, 28, 1195–1199. doi: 10.1002/oby.22831.
33. Milošević, I.; Jovanović, J.; Stevanović, O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. J Infect Dev Ctries. 2020, 14, 1248-1251. doi: 10.3855/jidc.13840.
34. Moore, J.L.;Ganapathiraju, P.V.; Kurtz, P.C.; Wainscoat, B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep. 2020, 21, e927812-1–e927812-5. doi: 10.12659/AJCR.927812.
35. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J. i saradnici. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323, 1061–1069. doi: 10.1001/jama.2020.1585.
36. Gupta, N.; Zhao, Y.Y. Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019, 181, 77–83. doi: 10.1016/j.thromres.2019.07.013.
37. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.J Thromb Haemost. 2020, 18, 1094-1099. doi: 10.1111/jth.14817.
38. Klok, F.A.; Kruip, J.H.A.; Meer, N.J.M.; Arbous, M.S.; Gommers, D.; Kant, K.M. i saradnici. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res. 2020, 191, 145–147. doi: 10.1016/j.thromres.2020.04.013.
39. Zhang, L.; Feng, X.; Zhang, D.; Jiang, C.; Mei, H.; Wang, J. i saradnici. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevelance, risk factors, outcome. Circulation AHA. 2020, 142, 114–128. doi: 10.1161/CIRCULATIONAHA.120.046702.
40. Jia, H.; Bijol, V.; Matthew, A.; Sise, M-E.; Izzedine, H.; Jhaveri K.D. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19.Adv Chronic Kidney Dis. 2020, 27, 365–376. doi: 10.1053/j.ackd.2020.09.003.
41. Cevik, M.; Tate, M.; Lloyd, O. i saradnici. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis. Lancet Microbe2020; (forthcoming) doi:10.1016/S2666-5247(20)30172-5.
42. Mahendiratta, S.; Batra, G.; Sarma, P.; Kumar, H.; Bansal, S.; Kumar, S.; Prakash, A.; Sehgal, R.; Medhi, B. Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. Life Sci. 2020, 258, 118207. doi: 10.1016/j.lfs.2020.118207.
43. Woloshin, S.; Patel, N.;. Kesselheim, A.S.False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications. N Engl J Med. 2020, 383:e38. doi: 10.1056/NEJMp2015897.
44. Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G. i saradnici . Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020, 323, 1843–1844. doi: 10.1001/jama.2020.3786.
45. Krajewski, R.; Gołębiowska, J.; Makuch, S.; Mazur, G.; Agrawal, S: Update on serologic testing in COVID-19. Clin Chim Acta. 2020, 510,746–750. 2020.doi: 10.1016/j.cca.2020.09.015.
46. Guo, L.; Ren, L.; Yang, S.; Xiao, M.; Chang, D.; Yang, F.; Dela Cruz, C.S.; Wang, Y.; Wu, C.; Xiao, Y. i saradnici. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020, 71, 778–785. doi: 10.1093/cid/ciaa310.
47. Pilarowski, G.; Lebel, P.; Sunshine, S.; Liu, J.; Crawford, E.; Marquez, C.; Rubio, L.; Chamie, G.; Martinez, J.; Peng, J. i saradnici. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021, 223, 1139-1144. doi: 10.1093/infdis/jiaa802.
48. Zhu, N.; Wang, W.; Liu, Z.; Liang, C.; Wang, W.; Ye, F.; Huang, B.; Zhao, L.; Wang, H.; Zhou, W. i saradnici. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020, 11, 3910. doi: 10.1038/s41467-020-17796-z.
49. Wang, M.; Fu, A.; Hu, B.; Tong, Y.; Liu, R.; Liu, Z.; Gu, J.; Xiang, B.; Liu, J.; Jiang, W. i saradnici. Nanopore targeted sequencing for the accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. Small. 2020, 16:e2002169. doi: 10.1002/smll.202002169.
50. Huang, W.E.; Lim, B.; Hsu, C.C.; Xiong, D.; Wu, W.; Yu, Y.; Jia, H.; Wang, Y.; Zeng, Y.; Ji, M. i saradnici. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol. 2020, 13, 950-961. doi: 10.1111/1751-7915.13586.
51. Falzone, L.; Gattuso, G.; Tsatsakis, A.; Spandidos, D-A.; Libra, M. Current and innovative methods for the diagnosis of COVID‑19 infection (Review).International Journalof MolecularMedicine. 2021, 47,https://doi.org/10.3892/ijmm.2021.4933.
52. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y. i saradnici. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5.
53. Fu, L.; Wang, B.; Yuan, T.; Chen, X.; Ao, Y.; Fitzpatrick, T. i saradnici. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020, 80, 656.doi: 10.1016/j.jinf.2020.03.041.
54. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z. i saradnici. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395, 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
55. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020, 18, 844–847. doi: 10.1111/jth.14768.
56. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J. i saradnici . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323, 1061–1069. doi: 10.1001/jama.2020.1585.
57. Kanne, J.P.; Little, B.P.; Chung, J.H.; Elicker, B.M.; Ketai, L.H. Essentials for radiologists on COVID-19: an update-radiology scientific expert panel. Radiology. 2020,296, E113-E114. doi: 10.1148/radiol.2020200527.
58. Shi, H.; Han, X.; Jiang, N.; Cao, Y.; Alwalid, O.;Gu, J. i saradnici. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020, 20, 425–434. doi: 10.1016/S1473-3099(20)30086-4.
59. Jacobi, A.; Chung, M.; Bernheim, A.; Eber, C. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clinical Imaging. 2020, 64, 35–42. doi: 10.1016/j.clinimag.2020.04.001.
60. Izda, V.; Jeffries, M.A.; Sawalhac, A.H. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021, 222, 108634. doi: 10.1016/j.clim.2020.108634.
61. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
62. Ikegame, S.; Siddiquey, M.; Hung, C.T.; Haas, G.; Brambilla, L.; Oguntuyo, K.; Kowdle, S.; Vilardo, A.; Edelstein, A.; Perandones, C.; Kamil, J.; Lee, B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. NIH Preprint Pilot.Preprint. 2021, doi: 10.21203/rs.3.rs-400230/v1.
63. Mahase, E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ.2020, 371:m4826. doi: 10.1136/bmj.m4826.
64. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z. i saradnici. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021, 21, 39–51. doi: 10.1016/S1473-3099(20)30831-8.
65. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A. i saradnici. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020, 396, 467–478. doi: 10.1016/S0140-6736(20)31604-4.
2. WHO. Clinical management of COVID-19: living guidance.Jan 25, 2021. Geneva: World Health Organization, 2021.
3. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science.2020, 367, 1444-1448. doi: 10.1126/science.abb2762.
4. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J. i saradnici. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020, 382,727-733. doi: 10.1056/NEJMoa2001017.
5. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006, 66,193–292. Doi: 10.1016/S0065-3527(06)66005-3.
6. Cevik, M.; Kuppalli, K.; Kindrachuk, J.; Peiris, M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020, 371. doi: 10.1136/bmj.m3862.
7. Shereen,MA.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020, 24, 91–8. doi: 10.1016/j.jare.2020.03.005.
8. Cheng, A.; Zhang, W.; Xie, Y.; Jiang, W.; Arnold, E.; Sarafianos, SG. i saradnici. Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology. 2005, 335, 165–176. doi: 10.1016/j.virol.2005.02.017.
9. Li, X.; Geng, M.; Peng, Y.; Meng, L.; Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020, 10, 102–108. doi: 10.1016/j.jpha.2020.03.001.
10. Li, G.; Fan, Y.; Lai, Y.; Han, T.; Li, Z.; Zhou, P. i saradnici. Coronavirus infections and immune responses. J Med Virol. 2020, 92, 424–432. doi: 10.1002/jmv.25685.
11. Zhou, Y.; Fu, B.; Zheng, X.; Wang, D.; Zhao, C.; Qi, Y.; Sun, R.; Tian, Z.; Xu, X.; Wei, H. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. National Science Review. 2020, 7, 998–1002.https://doi.org/10.1093/nsr/nwaa041.
12. Mahallawi, W.H.; Khabour, O.F.:, Zhang, Q.; Makhdoum, H.M.: Suliman, B.A. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018,104, 8–13. doi: 10.1016/j.cyto.2018.01.025.
13. Wong, C.K.; Lam, C.W.K.; Wu, A.K.L. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2014, 136, 95–103.doi: 10.1111/j.1365-2249.2004.02415.x.
14. Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46, 846–848. doi: 10.1007/s00134-020-05991-x.
15. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y. i saradnici . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.2020, 395,497–506. doi: 10.1016/S0140-6736(20)30183-5.
16. Dienz, O.; Rincon, M. The effects of IL-6 on CD4 T cell responses. Clin. Immunol.2009, 130, 27–33. doi:10.1016/j.clim.2008.08.018.
17. Yang, R.; Masters, A.R.; Fortner, K.A.; Champagne, D.P.; Yanguas-Casas, N.; Silberger, D.J.; Weaver, C.T.; Haynes, L.; Rincon, M. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells. J. Exp. Med. 2016, 213, 2281–2291. doi:10.1084/jem.20160417.
18. Hussman, J.P. Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention.Front Pharmacol.2020, 11, 1169. doi: 10.3389/fphar.2020.01169.
19. Varga, Z. Flammer, A.J.; Steiger, P.; Haberecker, M.; Andermatt, R. i saradnici. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020, 395, 1417-1418. doi:https://doi.org/10.1016/S0140-6736(20)30937-5.
20. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X. i saradnici. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382, 1708–1720. doi: 10.1056/NEJMoa2002032.
21. Bhatraju, P.K.; Ghassemieh, B.J.; Nichols, M.; Kim, R.; Jerome, K.R.; Nalla, A.K. i saradnici. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020, 382,2012–2022. doi: 10.1056/NEJMoa2004500.
22. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; Mcginn, T.; Davidson, K.W. i saradnici. Presenting characteristics, comorbidities, outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323, 2052–2059. doi:10.1001/jama.2020.6775.
23. Giacomelli, A.; Pezzati, L.; Conti, F.; Bernacchia, D.; Siano, M.; Oreni, L. i saradnici. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020, 71, 889-890.doi: 10.1093/cid/ciaa330.
24. Wang, Y.; Liu, Y.; Liu, L.; Wang, X.; Luo, N.; Ling, L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis. 2020, 221, 1770–1774. doi: 10.1093/infdis/jiaa119.
25. Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020, 25,2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
26. Pelemiš M.; Stevanović, G.; Turkulov, V.; Vučinić, V.; Matijašević, J.; Milošević, B.; Milošević, I. i saradnici. Nacionalni protokol Republike Srbije za lečenje COVID-19 infekcije,Verzija 11. 2021.
27. Wu, Z.; Mcgoogan, J.M. Characteristics of important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control Prevention. JAMA. 2020, 323, 1239–1242. doi: 10.1001/jama.2020.2648.
28. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z. i saradnici. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395, 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
29. Goyal, P.; Choi, J.J.; Pinheiro, L.C.; Schenck, E.J.; Chen, R.; Jabri, A. i saradnici . Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020, 382, 2372–2374. doi: 10.1056/NEJMc2010419.
30. Chow, N.; Fleming-Dutra, K.; Gierke, R.; Hall, A.; Hughes, M.; Pilishyili, T. i saradnici. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12-March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69, 382–386. doi: 10.15585/mmwr.mm6913e2.
31. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; Mcginn, T.; Davidson K.W. i saradnici. . Presenting characteristics, comorbidities, outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020, 323, 2052–2059. doi: 10.1001/jama.2020.6775.
32. Simonnet. A.; Chetboun, M.; Poissy, J.; Raverdy, V.; Noulette, J.; Duhamel, A. i saradnici. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020, 28, 1195–1199. doi: 10.1002/oby.22831.
33. Milošević, I.; Jovanović, J.; Stevanović, O. Atypical course of COVID-19 in patient with Bruton agammaglobulinemia. J Infect Dev Ctries. 2020, 14, 1248-1251. doi: 10.3855/jidc.13840.
34. Moore, J.L.;Ganapathiraju, P.V.; Kurtz, P.C.; Wainscoat, B. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma. Am J Case Rep. 2020, 21, e927812-1–e927812-5. doi: 10.12659/AJCR.927812.
35. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J. i saradnici. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323, 1061–1069. doi: 10.1001/jama.2020.1585.
36. Gupta, N.; Zhao, Y.Y. Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019, 181, 77–83. doi: 10.1016/j.thromres.2019.07.013.
37. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.J Thromb Haemost. 2020, 18, 1094-1099. doi: 10.1111/jth.14817.
38. Klok, F.A.; Kruip, J.H.A.; Meer, N.J.M.; Arbous, M.S.; Gommers, D.; Kant, K.M. i saradnici. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res. 2020, 191, 145–147. doi: 10.1016/j.thromres.2020.04.013.
39. Zhang, L.; Feng, X.; Zhang, D.; Jiang, C.; Mei, H.; Wang, J. i saradnici. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevelance, risk factors, outcome. Circulation AHA. 2020, 142, 114–128. doi: 10.1161/CIRCULATIONAHA.120.046702.
40. Jia, H.; Bijol, V.; Matthew, A.; Sise, M-E.; Izzedine, H.; Jhaveri K.D. Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19.Adv Chronic Kidney Dis. 2020, 27, 365–376. doi: 10.1053/j.ackd.2020.09.003.
41. Cevik, M.; Tate, M.; Lloyd, O. i saradnici. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis. Lancet Microbe2020; (forthcoming) doi:10.1016/S2666-5247(20)30172-5.
42. Mahendiratta, S.; Batra, G.; Sarma, P.; Kumar, H.; Bansal, S.; Kumar, S.; Prakash, A.; Sehgal, R.; Medhi, B. Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. Life Sci. 2020, 258, 118207. doi: 10.1016/j.lfs.2020.118207.
43. Woloshin, S.; Patel, N.;. Kesselheim, A.S.False Negative Tests for SARS-CoV-2 Infection — Challenges and Implications. N Engl J Med. 2020, 383:e38. doi: 10.1056/NEJMp2015897.
44. Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G. i saradnici . Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020, 323, 1843–1844. doi: 10.1001/jama.2020.3786.
45. Krajewski, R.; Gołębiowska, J.; Makuch, S.; Mazur, G.; Agrawal, S: Update on serologic testing in COVID-19. Clin Chim Acta. 2020, 510,746–750. 2020.doi: 10.1016/j.cca.2020.09.015.
46. Guo, L.; Ren, L.; Yang, S.; Xiao, M.; Chang, D.; Yang, F.; Dela Cruz, C.S.; Wang, Y.; Wu, C.; Xiao, Y. i saradnici. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020, 71, 778–785. doi: 10.1093/cid/ciaa310.
47. Pilarowski, G.; Lebel, P.; Sunshine, S.; Liu, J.; Crawford, E.; Marquez, C.; Rubio, L.; Chamie, G.; Martinez, J.; Peng, J. i saradnici. Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco. J Infect Dis. 2021, 223, 1139-1144. doi: 10.1093/infdis/jiaa802.
48. Zhu, N.; Wang, W.; Liu, Z.; Liang, C.; Wang, W.; Ye, F.; Huang, B.; Zhao, L.; Wang, H.; Zhou, W. i saradnici. Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. Nat Commun. 2020, 11, 3910. doi: 10.1038/s41467-020-17796-z.
49. Wang, M.; Fu, A.; Hu, B.; Tong, Y.; Liu, R.; Liu, Z.; Gu, J.; Xiang, B.; Liu, J.; Jiang, W. i saradnici. Nanopore targeted sequencing for the accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. Small. 2020, 16:e2002169. doi: 10.1002/smll.202002169.
50. Huang, W.E.; Lim, B.; Hsu, C.C.; Xiong, D.; Wu, W.; Yu, Y.; Jia, H.; Wang, Y.; Zeng, Y.; Ji, M. i saradnici. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol. 2020, 13, 950-961. doi: 10.1111/1751-7915.13586.
51. Falzone, L.; Gattuso, G.; Tsatsakis, A.; Spandidos, D-A.; Libra, M. Current and innovative methods for the diagnosis of COVID‑19 infection (Review).International Journalof MolecularMedicine. 2021, 47,https://doi.org/10.3892/ijmm.2021.4933.
52. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y. i saradnici. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5.
53. Fu, L.; Wang, B.; Yuan, T.; Chen, X.; Ao, Y.; Fitzpatrick, T. i saradnici. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020, 80, 656.doi: 10.1016/j.jinf.2020.03.041.
54. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z. i saradnici. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395, 1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
55. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020, 18, 844–847. doi: 10.1111/jth.14768.
56. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J. i saradnici . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323, 1061–1069. doi: 10.1001/jama.2020.1585.
57. Kanne, J.P.; Little, B.P.; Chung, J.H.; Elicker, B.M.; Ketai, L.H. Essentials for radiologists on COVID-19: an update-radiology scientific expert panel. Radiology. 2020,296, E113-E114. doi: 10.1148/radiol.2020200527.
58. Shi, H.; Han, X.; Jiang, N.; Cao, Y.; Alwalid, O.;Gu, J. i saradnici. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020, 20, 425–434. doi: 10.1016/S1473-3099(20)30086-4.
59. Jacobi, A.; Chung, M.; Bernheim, A.; Eber, C. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clinical Imaging. 2020, 64, 35–42. doi: 10.1016/j.clinimag.2020.04.001.
60. Izda, V.; Jeffries, M.A.; Sawalhac, A.H. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021, 222, 108634. doi: 10.1016/j.clim.2020.108634.
61. https://ourworldindata.org/covid-vaccinations?country=OWID_WRL
62. Ikegame, S.; Siddiquey, M.; Hung, C.T.; Haas, G.; Brambilla, L.; Oguntuyo, K.; Kowdle, S.; Vilardo, A.; Edelstein, A.; Perandones, C.; Kamil, J.; Lee, B. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. NIH Preprint Pilot.Preprint. 2021, doi: 10.21203/rs.3.rs-400230/v1.
63. Mahase, E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper shows. BMJ.2020, 371:m4826. doi: 10.1136/bmj.m4826.
64. Xia, S.; Zhang, Y.; Wang, Y.; Wang, H.; Yang, Y.; Gao, G.F.; Tan, W.; Wu, G.; Xu, M.; Lou, Z. i saradnici. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 2021, 21, 39–51. doi: 10.1016/S1473-3099(20)30831-8.
65. Folegatti, P.M.; Ewer, K.J.; Aley, P.K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E.A. i saradnici. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020, 396, 467–478. doi: 10.1016/S0140-6736(20)31604-4.
Published
2021/10/06
Section
Reviews